Analysts Expect Eagle Pharmaceuticals Inc (EGRX) to Post $1.02 EPS

Wall Street brokerages forecast that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce earnings per share (EPS) of $1.02 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings. The lowest EPS estimate is $0.94 and the highest is $1.09. Eagle Pharmaceuticals posted earnings of $0.53 per share during the same quarter last year, which would indicate a positive year over year growth rate of 92.5%. The business is expected to report its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $4.40 per share for the current financial year, with EPS estimates ranging from $4.12 to $4.80. For the next financial year, analysts anticipate that the firm will report earnings of $4.19 per share, with EPS estimates ranging from $3.55 to $4.83. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The business had revenue of $56.05 million during the quarter, compared to analysts’ expectations of $54.17 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis.

EGRX has been the subject of several recent research reports. BidaskClub cut shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 7th. Royal Bank of Canada set a $66.00 target price on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, March 1st. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $51.00 price target for the company in a research note on Monday, December 17th. Finally, ValuEngine upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $65.50.

EGRX traded down $0.31 during trading hours on Friday, hitting $47.02. 188,014 shares of the company’s stock were exchanged, compared to its average volume of 214,628. Eagle Pharmaceuticals has a 1-year low of $36.03 and a 1-year high of $85.66. The stock has a market capitalization of $659.02 million, a price-to-earnings ratio of 22.50 and a beta of 1.73. The company has a current ratio of 4.13, a quick ratio of 3.92 and a debt-to-equity ratio of 0.24.

In other Eagle Pharmaceuticals news, CEO Scott Tarriff sold 30,085 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $41.54, for a total value of $1,249,730.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 86,082 shares of company stock valued at $3,746,371. Corporate insiders own 28.20% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Eagle Pharmaceuticals by 21.6% in the third quarter. BlackRock Inc. now owns 1,741,712 shares of the specialty pharmaceutical company’s stock valued at $120,753,000 after purchasing an additional 309,622 shares during the period. Park West Asset Management LLC raised its position in shares of Eagle Pharmaceuticals by 41.6% in the fourth quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock valued at $42,304,000 after purchasing an additional 308,574 shares during the period. Iridian Asset Management LLC CT raised its position in shares of Eagle Pharmaceuticals by 8.7% in the third quarter. Iridian Asset Management LLC CT now owns 935,398 shares of the specialty pharmaceutical company’s stock valued at $64,851,000 after purchasing an additional 74,487 shares during the period. Vanguard Group Inc raised its position in shares of Eagle Pharmaceuticals by 9.7% in the third quarter. Vanguard Group Inc now owns 674,951 shares of the specialty pharmaceutical company’s stock valued at $46,794,000 after purchasing an additional 59,474 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Eagle Pharmaceuticals by 9.7% in the third quarter. Vanguard Group Inc. now owns 674,951 shares of the specialty pharmaceutical company’s stock valued at $46,794,000 after purchasing an additional 59,474 shares during the period. 92.54% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Story: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.